EHA 2023 | Phase II study of all-oral AAA regimen for patients with newly diagnosed APL
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, discusses an interim analysis of an ongoing, multicenter Phase II trial (NCT04687176) investigating an all-oral regimen of arsenic trioxide (ATO), all-trans retinoic acid (ATRA) and ascorbic acid (oral-AAA-based regimen) for the treatment of newly diagnosed acute promyelocytic leukemia (APL). Dr Gill shares the promising results for patients achieving complete remission (CR) and complete molecular response (CMR) and goes on to comment on further efficacy and safety data. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Disclosures: Consultancy and advisory board – BMS, GSK, Novartis, Pfizer, PharmaEssentia; Investigator-initiated study collaboration – Imago Biosciences, Novartis, PharmaEssentia
